Keyphrases
Randomized Controlled Trial
58%
Placebo
58%
Miscarriage
51%
Progesterone
41%
Missed Abortion
41%
Misoprostol
41%
Mifepristone
41%
Uterine Artery Embolization
41%
Myomectomy
41%
Confidence Interval
35%
Cost-effectiveness
35%
Thyroid Peroxidase Antibody (TPOAb)
32%
Live Birth
31%
Levothyroxine
31%
Uterine Fibroids
31%
Misoprostol Alone
30%
Economic Evaluation
29%
Abnormal Uterine Bleeding
29%
Early Pregnancy Bleeding
27%
Pilot Randomized Controlled Trial
27%
People Experiencing Homelessness
27%
Community Pharmacy
27%
Euthyroid Women
21%
Early Pregnancy
19%
Randomized Placebo-controlled Trial
17%
Hysterectomy
17%
Postmenopausal Women
17%
Bleeding
16%
Placebo Groups
16%
Trying to Conceive
15%
Homeless Outreach
15%
Third Sector
15%
Levonorgestrel-releasing Intrauterine System (LNG-IUS)
15%
Independent Prescribing
15%
Non-medical
15%
Nulliparous Women
15%
Randomized Trial
15%
Polyps
13%
Estrogen Treatment
13%
Polypectomy
13%
Multicenter Trial
13%
Pelvic Organ Prolapse Surgery
13%
Estrogen
13%
Placebo-controlled Trial
13%
Euthyroid
13%
Hypothyroidism
13%
Oxytocin
13%
High Dose
13%
Lotus
13%
Atorvastatin
13%
Medicine and Dentistry
Randomized Controlled Trial
100%
Spontaneous Abortion
55%
Placebo
54%
Bleeding
46%
First Trimester Pregnancy
41%
Progesterone
41%
Uterine Artery Embolization
41%
Uterine Myomectomy
41%
Uterine Fibroid
34%
Misoprostol
27%
Mifepristone
27%
Health Care Cost
26%
Cost-Effectiveness Analysis
25%
Quality of Life
23%
Menorrhagia
17%
Hysterectomy
16%
Levonorgestrel
15%
Nulliparous
14%
Outpatient
13%
Estrogen Therapy
13%
Gestagen
13%
Polyp
13%
Uterus Bleeding
13%
Endometriosis
13%
Recurrent Disease
13%
Postmenopause
13%
Pelvic Organ Prolapse
13%
Drug Megadose
13%
Large Multicenter Trial
13%
Oral Contraceptive Agent
13%
Oxytocin
13%
Ulipristal
13%
Personal Experience
13%
Community Pharmacy
13%
Phase III Trials
13%
Polypectomy
12%
Quality Adjusted Life Year
10%
Mifepristone Plus Misoprostol
8%
Adverse Event
7%
Vaginal Delivery
6%
Supplementation
5%
Embolization
5%
Vagina Bleeding
5%